Frederick Telling - Oragenics Independent Chairman of the Board
| OGEN Stock | USD 0.23 0.02 6.40% |
Chairman
Dr. Frederick W. Telling, Ph.D., was an Independent Chairman of the Board of ORAGENICS, INC. He has served as a Director since June 2010. Dr. Telling retired from Pfizer Inc. in June 2007 after 30 years of service. At Pfizer Dr. Telling served as its Corporationrationrate Vice President and Vice President of Corporationrationrate Strategic Planning and Policy since October 1994. Dr. Telling also serves as a director and member of the Compensation Committee and Audit Committee at Cell Therapeutics Inc., a public company based in Seattle, Washington. Dr. Telling also serves on the boards of various civic and nonprofit organizations.Dr. Telling brings to our Board an extensive array of business and industry experience as well as experience as a director of public companies since 2011.
| Age | 72 |
| Tenure | 14 years |
| Professional Marks | Ph.D |
| Address | 4902 Eisenhower Boulevard, Tampa, FL, United States, 33634 |
| Phone | 813 286 7900 |
| Web | https://www.oragenics.com |
Oragenics Management Efficiency
The company has return on total asset (ROA) of (2.0498) % which means that it has lost $2.0498 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.1495) %, meaning that it created substantial loss on money invested by shareholders. Oragenics' management efficiency ratios could be used to measure how well Oragenics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Oragenics' Return On Capital Employed is very stable compared to the past year. As of the 27th of March 2025, Return On Equity is likely to grow to 52.37, though Return On Tangible Assets are likely to grow to (6.82). At this time, Oragenics' Other Assets are very stable compared to the past year. As of the 27th of March 2025, Non Currrent Assets Other is likely to grow to about 1.3 M, while Total Assets are likely to drop about 1.4 M.Management Performance
| Return On Equity | -7.15 | ||||
| Return On Asset | -2.05 |
Oragenics Leadership Team
Elected by the shareholders, the Oragenics' board of directors comprises two types of representatives: Oragenics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oragenics. The board's role is to monitor Oragenics' management team and ensure that shareholders' interests are well served. Oragenics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oragenics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Martin MSc, VP Research | ||
| MD MA, Chief Advisor | ||
| IV FACEP, Chief Officer | ||
| Kimberly Murphy, CEO Director | ||
| Erik Emerson, Chief Officer | ||
| Janet Huffman, President, CEO | ||
| Michael CPA, S CFO | ||
| Charles CPA, Executive Chairman | ||
| Christine Farrell, Vice Finance | ||
| Joseph Redmond, President Officer | ||
| Frederick Telling, Independent Chairman of the Board | ||
| Greg Gironda, Chief Officer |
Oragenics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Oragenics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.15 | ||||
| Return On Asset | -2.05 | ||||
| Current Valuation | 4.87 M | ||||
| Shares Outstanding | 21.48 M | ||||
| Shares Owned By Insiders | 13.00 % | ||||
| Shares Owned By Institutions | 1.14 % | ||||
| Number Of Shares Shorted | 312.64 K | ||||
| Price To Earning | (2.28) X | ||||
| Price To Book | 2.35 X | ||||
| Price To Sales | 89.28 X |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oragenics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Oragenics Stock, please use our How to Invest in Oragenics guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oragenics. If investors know Oragenics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oragenics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Oragenics is measured differently than its book value, which is the value of Oragenics that is recorded on the company's balance sheet. Investors also form their own opinion of Oragenics' value that differs from its market value or its book value, called intrinsic value, which is Oragenics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oragenics' market value can be influenced by many factors that don't directly affect Oragenics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oragenics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oragenics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oragenics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.